Atara Biotherapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-95.1% -$31M
$2M
R&D↓-93.3% -$41M
$3M
D&A↓-95.5% -$1M
$49K
Operating Income↑+83.6% +$18M
$-4M
EBITDA↓-95.5% -$1M
$49K
Interest Expense↓-12.1% -$123K
$894K
Interest Income↓-83.2% -$497K
$100K
Other Income/Expense↓-99.3% -$551K
$4K
Pretax Income↑+80.5% +$18M
$-4M
Tax Provision
$0
Net Income↑+80.4% +$18M
$-4M
Operating Margin↓-49.4pts
-103.5%
Net Margin↓-70.1pts
-124.6%
Effective Tax Rate↓-0.7pts
-0.7%
ETR (Continuing Operations)↑+0.1pts
0.1%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)
-0.3%
ETR Foreign Differential (pp)
—
Operating Lease Cost↓-91.4% -$4M
$350K
Revenue YoY Variation↓-765.4pts
-95.1%
Income YoY Variation↑+14.8pts
83.6%
Revenue QoQ Variation↓-35.3pts
-53.8%
Income QoQ Variation↓-192.5pts
-211.8%